Japan'€™s most admired pharma companies in 2010 by P Reed Maurer

International Alliances Limited (IAL), headed by P Reed Maurer, has presented the results of its 12th annual survey of Japan’s most admired pharma companies. A summary of the report follows, but the complete analysis is available from IAL for 30,000 yen, 10% of which will be donated to the Children’s Cancer Association of Japan. To order, contact IAL as follows: Tel: 03-3401-4375. Fax:03-3401-5715 Email: nppial@gol.com

Methodology
30 companies, 15 Japanese, and 15 foreign affiliates were evaluated. They included: Japanese: Astellas, Asahi Kasei, Daiichi-Sankyo, Eisai, Kaken, Kyorin, Kyowa Hakko Kirin, Mitsubishi Tanabe, Mochida, Otsuka, Santen, Shionogi, Takeda and Zeria.
Foreign: Abbott, Alcon, AstraZeneca, Bayer Yakuhin, Bristol-Myers Squibb, Chugai, Eli Lilly, GlaxoSmithKline, MSD (Merck & Co), Nippon Boehringer Ingelheim, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis, UCB.

Each company was evaluated on eight categories of performance: Quality of Management; Quality of Products; Potential for Growth; New Drug Discovery Potential; Quality of Development; Quality of MRs; Profitability in the Future; Overall Opinion.